The Asia Pacific pharmaceutical gelatin industry is evolving beyond its historical role as a standard drug enclosure material. Today, gelatin is at the core of therapeutic delivery innovations, serving as a critical functional excipient for difficult-to-solubilize Active Pharmaceutical Ingredients (APIs), targeted oral release systems, and specialty medical biomaterials.
Rising chronic disease burdens across India, China, Japan, and Southeast Asia have escalated the demand for oral solid dosage forms that maximize patient compliance through taste-masking, moisture barriers, and rapid gastric release. Concurrently, global drug innovators are dual-sourcing capsule supplies from Asian manufacturing clusters to guard against supply chain vulnerabilities. This shift is spurring unprecedented investments in ultra-pure, endotoxin-controlled gelatin grades capable of supporting biological drugs, vaccines, and advanced wound-care hemostats.
Key Findings from the Report
Revenue Milestone: The APAC Pharmaceutical Gelatin Market will grow from USD 552.77 Million in 2024 to USD 768.22 Million by 2032, gaining steady momentum across oral solid and softgel formulations.
Hard Capsules Dominance: Hard gelatin capsules captured over 70% of market volume, reinforced by their role as the preferred delivery vehicle for oral solid generics, vitamins, and dry powder inhalers.
Porcine Source Leadership: The porcine gelatin segment maintains the largest volume share, benefiting from cost-effective extraction, high gel strength (Bloom value), and abbreviated production cycles.
Surge in Marine Gelatin: Marine-derived gelatin is recording the fastest growth rate, propelled by strong demand for Halal-certified products and supply chain diversification away from land animal risks.
Regional Anchor: China remains the largest single market in terms of revenue, underpinned by massive domestic drug production and expanding healthcare coverage.
Growth Engine: India represents the fastest-growing market, driven by expanding CDMO activities, major capsule capacity additions, and favorable government incentives for domestic active ingredient and excipient processing.
For further information, click the following link: https://www.stellarmr.com/report/req_sample/APAC-Pharmaceutical-Gelatin-Market/1238
Market Drivers and Restraints
Market Drivers
Surging Preference for Solid Oral Dosage Forms: Gelatin’s unique bio-functional characteristics—such as thermo-reversibility, oxygen barrier protection, and rapid disintegration—make it indispensable for high-speed capsule filling lines.
Cost-Efficient Manufacturing Ecosystems: Low operating capital requirements, skilled technical labor, and abundant access to bovine and porcine raw materials across APAC allow regional producers to achieve superior economies of scale.
Expansion of Softgel & Solubilization Technologies: As modern pharmaceutical pipelines yield increasingly hydrophobic APIs, formulators rely heavily on gelatin-based softgel capsules to enhance bio-availability.
Market Restraints
Upstream Raw Material Volatility: Fluctuations in livestock production, coupled with strict disease-free certification standards (such as BSE/TSE compliance), create supply periodic bottlenecks.
Competition from Plant-Based Alternatives: Growing consumer demand for vegetarian and vegan products has accelerated the adoption of HPMC (hydroxypropyl methylcellulose) capsules, prompting gelatine manufacturers to innovate with high-performance specialty grades.
Technology, Regulation, and Sustainability Trends
3D-Printed Drug Matrices: Gelatin methacryloyl (GelMA) and custom-bloomed pharmaceutical gelatins are entering pilot production stages for 3D-printed personalized therapeutics, enabling multi-drug polypills with targeted dissolution profiles.
Ultra-Low Endotoxin Compliance: Biopharmaceutical applications, such as biostabilizers for vaccines and plasma expanders, require rigorous endotoxin control. Manufacturers are retrofitting processing plants with advanced membrane filtration technology.
ESG & Sustainable Sourcing: Industry leaders are transitioning toward closed-loop water treatment systems and carbon-neutral extraction processes to meet international sustainability benchmarks demanded by Western pharmaceutical buyers.
Recent Industry Developments
Darling Ingredients Inc. & Tessenderlo Group (Dec 2025): Signed a definitive agreement to form Nextida, unifying their collagen and gelatin divisions to streamline supply chains and meet expanding pharmaceutical demand in APAC and global markets.
India Gelatine & Chemicals Ltd (Nov 2025): Announced a major plant expansion project to upgrade processing lines, expanding total gelatine production capacity from 2,000 MT to 2,700 MT to support domestic and international capsule manufacturers.
Rousselot (Sep 2025): Introduced next-generation high-purity gelatin prototypes designed specifically as medical-grade biomaterials for specialized drug delivery vehicles and surgical dressings.
Nitta Gelatin (June 2025): Unveiled an advanced pharmaceutical gelatin grade featuring optimized solubility and fast dissolution metrics, specifically engineered for precision-targeted therapeutics and softgels.
PB Leiner (May 2025): Launched a dedicated eco-friendly pharmaceutical gelatin product portfolio emphasizing zero-waste sourcing and low-carbon manufacturing to align with global green pharma initiatives.
For further information, click the following link: https://www.stellarmr.com/report/req_sample/APAC-Pharmaceutical-Gelatin-Market/1238
Competitive Landscape
The Asia Pacific pharmaceutical gelatin market features a balance of established global suppliers and rapidly growing regional processors. Key players are executing aggressive growth strategies, including local production line expansions, strategic joint ventures, and specialized portfolio diversification into BSE-free and Halal-certified grades.
Nitta Gelatin Inc. (Japan)
Xiamen Gelatin Co. (China)
Henan Boom Gelatin (China)
Jellice Taiwan (Taiwan)
Sterling Gelatin (India)
Softsule (India)
Rousselot (Darling Ingredients)
PB Leiner (Tessenderlo Group)
Analyst Commentary
"The Asia Pacific region is rapidly evolving from a low-cost sourcing center into a high-precision manufacturing hub for pharmaceutical gelatin," said a Senior Research Analyst at Stellar Market Research.
"As global pharmaceutical companies re-evaluate their supply chains to guard against localized disruptions, APAC’s robust ecosystem of capsule manufacturers, combined with local raw material access and investments in endotoxin-controlled grades, positions the region as an irreplaceable growth engine for oral solid and injectable drug delivery systems through 2032."
Future Outlook
Through 2032, the APAC pharmaceutical gelatin market will experience sustained structural expansion. Demand will be buoyed by the growing adoption of complex softgel formulations for lipophilic drugs, the scaling up of local CDMO production lines in India and Southeast Asia, and breakthroughs in 3D-bioprinted delivery systems. Gelatin producers that prioritize traceable, sustainably sourced, and low-endotoxin grades will capture premium market share across both regional and international regulated healthcare markets.
About US: Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Address
Phase 3, Navale IT Zone, S.No. 51/2A/2, Office No. 202, 2nd floor, Near, Navale Brg, Narhe, Pune, Maharashtra 411041
Email
[email protected]
Mobile
+91 9607365656
Comments